<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702407</article-id><article-id pub-id-type="doi">10.26442/00403660.2026.05.203608</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunoglobulin G4-related retroperitoneal fibrosis: clinical, laboratory, imaging, and histopathological features in a Russian single-center cohort</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуноглобулин G4-связанный ретроперитонеальный фиброз: клинико-лабораторные, инструментальные и патоморфологические характеристики российской когорты</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-7621-5833</contrib-id><name-alternatives><name xml:lang="en"><surname>Veretennikov</surname><given-names>Aleksei S.</given-names></name><name xml:lang="ru"><surname>Веретенников</surname><given-names>Алексей Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>аспирант</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8099-2107</contrib-id><name-alternatives><name xml:lang="en"><surname>Torgashina</surname><given-names>Anna V.</given-names></name><name xml:lang="ru"><surname>Торгашина</surname><given-names>Анна Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. лаб. редких ревматических заболеваний и болезни Шегрена</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4188-3578</contrib-id><name-alternatives><name xml:lang="en"><surname>Chaltsev</surname><given-names>Bogdan D.</given-names></name><name xml:lang="ru"><surname>Чальцев</surname><given-names>Богдан Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. лаб. редких ревматических заболеваний и болезни Шегрена</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1082-8659</contrib-id><name-alternatives><name xml:lang="en"><surname>Kovrigina</surname><given-names>Alla M.</given-names></name><name xml:lang="ru"><surname>Ковригина</surname><given-names>Алла Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р биол. наук, зав. патологоанатомическим отд-нием, проф. Института клинической морфологии и цифровой патологии</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2314-1466</contrib-id><name-alternatives><name xml:lang="en"><surname>Khvan</surname><given-names>Julia I.</given-names></name><name xml:lang="ru"><surname>Хван</surname><given-names>Юлия Иннокентиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. редких ревматических заболеваний и болезни Шегрена</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3183-0464</contrib-id><name-alternatives><name xml:lang="en"><surname>Dibrov</surname><given-names>Danil A.</given-names></name><name xml:lang="ru"><surname>Дибров</surname><given-names>Данил Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. редких ревматических заболеваний и болезни Шегрена</p></bio><email>averetennikov03@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» Минобрнауки России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center for Hematology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-06-13" publication-format="electronic"><day>13</day><month>06</month><year>2026</year></pub-date><volume>98</volume><issue>5</issue><issue-title xml:lang="en">Issues of rheumatology</issue-title><issue-title xml:lang="ru">Вопросы ревматологии</issue-title><fpage>306</fpage><lpage>313</lpage><history><date date-type="received" iso-8601-date="2026-02-09"><day>09</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-20"><day>20</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/702407">https://ter-arkhiv.ru/0040-3660/article/view/702407</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> To describe a Russian cohort of patients with IgG4-related retroperitoneal fibrosis (RPF).</p> <p><bold>Materials and methods.</bold> This retrospective single-center study included 36 patients diagnosed with IgG4-related RPF according to the revised 2020 diagnostic criteria. Clinical, laboratory, instrumental, and pathomorphological data were analyzed.</p> <p><bold>Results.</bold> The cohort of 36 patients with IgG4-related RPF predominantly comprised males (4:1 ratio), with a median onset age of 52 years and median time to diagnosis of 8 months. The disease most presented with low back or lower abdominal pain (75%), renal dysfunction (44%), elevated serum IgG4&gt;1.35 g/L (82%), and increased ESR/CRP. Urinary tract infection was detected in 44% due to frequent ureteral catheterization. Isolated retroperitoneal involvement occurred in 72% of cases, with typical infrarenal periaortitis in 58%; atypical sites included perirenal, periureteral, and presacral localizations. Biopsy (<italic>n</italic>=23) revealed lymphoplasmacytic infiltrate (100%), fibrosis (87%), IgG4+/CD138+&gt;40% (71%), with obliterative phlebitis (26%) and tissue eosinophilia (26%) less common.</p> <p><bold>Conclusion.</bold> Compared to international data, our findings reveal a higher prevalence of atypical localizations and concomitant urinary tract infections, necessitating their consideration in diagnostic algorithms and treatment planning for RPF patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Описать российскую когорту пациентов с иммуноглобулин (Ig)G4-связанным ретроперитонеальным фиброзом (РПФ).</p> <p><bold>Материалы и методы.</bold> В ретроспективное одноцентровое исследование включены 36 пациентов с диагнозом IgG4-связанного РПФ в соответствии с пересмотренными диагностическими критериями 2020 г. Анализировались клинико-лабораторные, инструментальные, патоморфологические данные пациентов.</p> <p><bold>Результаты.</bold> В когорте из 36 пациентов с IgG4-связанным РПФ преобладали мужчины (соотношение 4:1), медиана возраста дебюта – 52 года, время до постановки диагноза – 8 мес. Наиболее часто заболевание характеризовалось болью в пояснице или нижних отделах живота (75%), нарушением функции почек (44%), повышением сывороточного IgG4&gt;1,35 г/л (82%), повышенными скоростью оседания эритроцитов/С-реактивным белком. В связи с высокой частотой катетеризации мочеточников у 44% пациентов выявлена мочевая инфекция. Изолированное поражение забрюшинного пространства наблюдалось в 72% случаев, типичная локализация РПФ в виде инфраренального периаортита – в 58%, среди атипичных локализаций отмечались околопочечная, околомочеточниковая, пресакральная. Биопсия (<italic>n</italic>=23) выявила лимфоплазмоцитарный инфильтрат (100%), фиброз (87%), IgG4+/CD138+&gt;40% (71%), реже наблюдались облитерирующий флебит (26%) и эозинофильная инфильтрация (26%).</p> <p><bold>Заключение.</bold> При сравнении с зарубежными данными отмечается более высокая частота атипичных локализаций и сопутствующей инфекции мочевыводящих путей, что существенно влияет на диагностические алгоритмы и выбор терапевтической тактики у пациентов с РПФ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>IgG4-related disease</kwd><kwd>retroperitoneal fibrosis</kwd><kwd>Ormond’s disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>IgG4-связанное заболевание</kwd><kwd>ретроперитонеальный фиброз</kwd><kwd>болезнь Ормонда</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The article was conducted as part of the scientific research work of the Nasonova Research Institute of Rheumatology. State registration No. 125020501434-1.</funding-statement><funding-statement xml:lang="ru">Статья подготовлена в рамках научно-исследовательской работы ФГБНУ «НИИР им. В.А. Насоновой», государственное задание №125020501434-1.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford). 2025;64(suppl.1):i24-7. DOI:10.1093/rheumatology/keaf008</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wallace ZS, Miles G, Smolkina E, et al. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis. 2023;82(7):957-62. DOI:10.1136/ard-2023-223950</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Сокол Е.В. Новые классификационные критерии IgG4-связанного заболевания Американской коллегии ревматологов (ACR)/Европейской антиревматической лиги (EULAR), 2019. Научно-практическая ревматология. 2020;58(4):368-75 [Sokol EV. The new 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for lgG4-related disease. Rheumatology Science and Practice. 2020;58(4):368-75 (in Russian)]. DOI:10.47360/1995-4484-2020-368-375</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020;72(1):7-19. DOI:10.1002/art.41120</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31(3): 529-33. DOI:10.1080/14397595.2020.1859710</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mizushima I, Morikage N, Ito E, et al. Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease. Circ J. 2024;88(10):1679-88. DOI:10.1253/circj.CJ-24-0026</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Сокол Е.В., Васильев В.И., Пальшина С.Г., и др. Клинико-лабораторная характеристика IgG4-связанного заболевания и алгоритм его диагностики. Терапевтический архив. 2019;91(5):40-8 [Sokol EV, Vasilyev VI, Palshina SG, et al. Clinical and laboratory characteristics of IgG4-realated disease and its diagnostic algorithm. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(5):40-8 (in Russian)]. DOI:10.26442/00403660.2019.05.000236</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kawano M, Zen Y, Saeki T, et al. IgG4-related disease. In: Stone JH, ed. A Clinician’s Pearls &amp; Myths in Rheumatology. Cham: Springer International Publishing, 2023; p. 701-25.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kranz J, Bartoletti R, Bruyère F, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol. 2024;86(1):27-41. DOI:10.1016/j.eururo.2024.03.035</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406-12. DOI:10.1136/annrheumdis-2018-214603</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore). 2009;88(4):202-7. DOI:10.1097/MD.0b013e3181afc439</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009;88(4): 193-201. DOI:10.1097/MD.0b013e3181afc420</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One. 2021;16(2):e0245601. DOI:10.1371/journal.pone.0245601</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hu JQ, Jin ZY, Yu YY, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis in a cohort of 117 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Clin Rheumatol. 2025;44(2):757-66. DOI:10.1007/s10067-024-07276-w</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mitchinson MJ. Aortic disease in idiopathic retroperitoneal and mediastinal fibrosis. J Clin Pathol. 1972;25(4):287-93. DOI:10.1136/jcp.25.4.287</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241-51. DOI:10.1016/S0140-6736(06)68035-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ершова А.И., Балахонова Т.В., Мешков А.Н., и др. Распространенность атеросклероза сонных и бедренных артерий среди населения Ивановской области: исследование АТЕРОГЕН-Иваново. Кардиоваскулярная терапия и профилактика. 2021;20(5):2994 [Ershova AI, Balakhonova TV, Meshkov AN, et al. Prevalence of carotid and femoral artery atherosclerosis among the Ivanovo Oblast population: data from the ATEROGEN-Ivanovo study. Cardiovascular Therapy and Prevention. 2021;20(5):2994 (in Russian)]. DOI:10.15829/1728-8800-2021-2994</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Goldoni M, Bonini S, Urban ML, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med. 2014;161(3):181-8. DOI:10.7326/M13-2648</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet. 2004;363(9419):1422-6. DOI:10.1016/S0140-6736(04)16100-X</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86(4):297-303. DOI:10.4065/mcp.2010.0663</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford). 2020;59(9):2435-42. DOI:10.1093/rheumatology/keaa221</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mizushima I, Kasashima S, Fujinaga Y, et al. Clinical and Pathological Characteristics of IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis Diagnosed Based on Experts’ Diagnosis. Ann Vasc Dis. 2019;12(4):460-72. DOI:10.3400/avd.oa.19-0008</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol. 2009;23(3):339-53. DOI:10.1016/j.berh.2008.12.002</mixed-citation></ref></ref-list></back></article>
